| Auteur | |
|---|---|
| jiraporn66 | 22 Aug 2021 - 07:48:29 |
| 470 Posts |
 Danish pharmaceuticalslotcompany Announcing progress on new COVID-19 vaccine trials Paul Chaplin, President and CEO of Bavarian Nordic, a Danish pharmaceutical company. The development of a new COVID-19 vaccine, "ABNCoV2," based on virus-like protein-like protein (cVLP) shell technology, has completed a phase I clinical trial in humans. to be effective in building immunity It can produce immune levels that are superior to currently approved vaccines. And it is continuing its Phase 2 trials later this month. To assess the potential use of the universal booster vaccine in the future. This vaccine trial It was developed in collaboration with researchers from the University of Copenhagen. The trial was conducted on 45 volunteers at the Rudboud University Medical Center in the Netherlands. The researchers found that the subjects had antibody levels or immunity up to 12 times higher than those infected with COVID-19 after two doses of the vaccine. |
  |
|
